Tasocitinib + Tasocitinib + vehicle for Tasocitinib
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Keratoconjunctivitis Sicca
Conditions
Keratoconjunctivitis Sicca
Trial Timeline
Dec 1, 2010 → Oct 19, 2012
NCT ID
NCT01226680About Tasocitinib + Tasocitinib + vehicle for Tasocitinib
Tasocitinib + Tasocitinib + vehicle for Tasocitinib is a phase 2 stage product being developed by Pfizer for Keratoconjunctivitis Sicca. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01226680. Target conditions include Keratoconjunctivitis Sicca.
What happened to similar drugs?
1 of 9 similar drugs in Keratoconjunctivitis Sicca were approved
Approved (1) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01226680 | Phase 2 | Withdrawn |
Competing Products
15 competing products in Keratoconjunctivitis Sicca
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FK506 | Astellas Pharma | Phase 3 | 40 |
| FK506 + placebo | Astellas Pharma | Phase 3 | 40 |
| OTX-101 0.09% | Sun Pharmaceutical | Phase 3 | 40 |
| OTX-101 0.05% + OTX-101 0.09% + Vehicle | Sun Pharmaceutical | Phase 2/3 | 38 |
| cyclosporine + vehicle of OTX-101 | Sun Pharmaceutical | Phase 3 | 40 |
| INS365 Ophthalmic Solution | Merck | Phase 3 | 40 |
| Pimecrolimus + Vehicle | Novartis | Phase 2 | 35 |
| Cyclosporine A + Dexamethasone | Novartis | Approved | 43 |
| Rebamipide | Novartis | Phase 3 | 40 |
| Rebamipide | Novartis | Phase 3 | 40 |
| Dupilumab | Regeneron Pharmaceuticals | Phase 2 | 31 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo | Rigel Pharmaceuticals | Phase 1 | 23 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo | Rigel Pharmaceuticals | Phase 2 | 29 |
| CF101 | Can Fite Biopharma | Phase 3 | 30 |
| CF101 + Placebo | Can Fite Biopharma | Phase 2 | 25 |